Karuna Therapeutics, Inc. was a clinical-stage biopharmaceutical company focused on developing transformative medicines for neuropsychiatric disorders. The company was acquired by Bristol-Myers Squibb in March 2024.
Founded in 2009 as Karuna Pharmaceuticals, the company developed KarXT (xanomeline-trospium), a novel muscarinic receptor agonist with potential applications in schizophrenia and psychosis associated with Alzheimer's disease["@karuna"].
Funding
...
Karuna Therapeutics, Inc. was a clinical-stage biopharmaceutical company focused on developing transformative medicines for neuropsychiatric disorders. The company was acquired by Bristol-Myers Squibb in March 2024.
Overview
Mermaid diagram (expand to render)
Founded in 2009 as Karuna Pharmaceuticals, the company developed KarXT (xanomeline-trospium), a novel muscarinic receptor agonist with potential applications in schizophrenia and psychosis associated with Alzheimer's disease["@karuna"].
Funding
IPO: 2019 (NASDAQ: KRTX)
Acquired: 2024 by Bristol-Myers Squibb ($14B)
Prior Funding: Series A-C
Company History
Founded: 2009
Headquarters: Boston, Massachusetts
Founded By: Dr. Jeffrey L. Apter, Dr. John R. M. Kem
Acquired: Bristol-Myers Squibb (March 2024)
Employees: Approximately 300 at acquisition
History and Development
Early Development (2009-2018)
Karuna was founded based on research from Yale University and the University of Minnesota on muscarinic receptor biology. The company's founding insight was that muscarinic receptor activation could treat psychosis without the dopamine-blocking side effects of traditional antipsychotics.
Clinical Development (2018-2023)
2018: Initiated Phase 1 trials for KarXT
2019: Completed Phase 1 showing safety and tolerability
2021: Started EMERGENT Phase 3 program in schizophrenia
Deal Value: Approximately $14.6 billion USD ($330 per share)
Strategic Rationale: BMS sought to strengthen its neuroscience portfolio and gain access to novel neuropsychiatric treatments[@karunaa]
The acquisition represented one of the largest CNS deals in pharmaceutical history, validating Karuna's innovative approach to muscarinic receptor targeting.
Key Pipeline: KarXT (Xanomeline-Trospium)
Mechanism of Action
KarXT is a novel muscarinic receptor agonist that selectively targets M1 and M4 muscarinic acetylcholine receptors while avoiding D2 dopamine receptor blockade. This represents a fundamentally different mechanism from current antipsychotics[@karxt]:
Xanomeline: Muscarinic agonist (M1/M4 selective)
Trospium: Peripheral muscarinic antagonist (limits side effects)
Net Effect: Central nervous system muscarinic activation without peripheral toxicity
Why Muscarinic Agonism for Psychosis?
The cholinergic hypothesis of psychosis suggests that:
M1 receptor activation may improve cognitive function
M4 receptor activation may reduce psychotic symptoms
Muscarinic dysfunction contributes to treatment-resistant symptoms